Novavax (NVAX) Trading Down 5.1%
Novavax, Inc. (NASDAQ:NVAX) shares traded down 5.1% on Tuesday . The company traded as low as $1.31 and last traded at $1.31. 4,619,725 shares were traded during trading, a decline of 22% from the average session volume of 5,916,180 shares. The stock had previously closed at $1.38.
A number of research analysts recently weighed in on the stock. Zacks Investment Research raised shares of Novavax from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a research report on Wednesday, August 16th. BidaskClub raised shares of Novavax from a “sell” rating to a “hold” rating in a research report on Monday, August 14th. Seaport Global Securities reissued a “neutral” rating on shares of Novavax in a research report on Friday, October 6th. Cantor Fitzgerald reissued a “hold” rating and set a $2.00 price target on shares of Novavax in a research report on Wednesday, November 8th. Finally, Citigroup raised shares of Novavax from a “neutral” rating to a “buy” rating and set a $2.00 price target on the stock in a research report on Tuesday, October 31st. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $3.12.
The company has a debt-to-equity ratio of -4.28, a current ratio of 3.31 and a quick ratio of 3.31.
Novavax (NASDAQ:NVAX) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. Novavax had a negative net margin of 726.35% and a negative return on equity of 787.38%. The company had revenue of $8.35 million for the quarter, compared to analyst estimates of $6.42 million. During the same period last year, the firm earned ($0.24) earnings per share. The firm’s revenue was up 158.5% on a year-over-year basis. equities research analysts anticipate that Novavax, Inc. will post -0.62 earnings per share for the current year.
In related news, insider Stanley C. Erck acquired 100,000 shares of the stock in a transaction on Thursday, November 9th. The shares were acquired at an average price of $1.13 per share, with a total value of $113,000.00. Following the completion of the transaction, the insider now owns 228,279 shares in the company, valued at approximately $257,955.27. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 4.00% of the company’s stock.
A number of hedge funds have recently made changes to their positions in NVAX. Raymond James Financial Services Advisors Inc. raised its position in Novavax by 49.8% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 89,697 shares of the biopharmaceutical company’s stock worth $103,000 after acquiring an additional 29,800 shares during the period. Profund Advisors LLC raised its position in Novavax by 0.4% in the second quarter. Profund Advisors LLC now owns 120,775 shares of the biopharmaceutical company’s stock worth $139,000 after acquiring an additional 455 shares during the period. Voya Investment Management LLC raised its position in Novavax by 18.6% in the second quarter. Voya Investment Management LLC now owns 138,270 shares of the biopharmaceutical company’s stock worth $159,000 after acquiring an additional 21,639 shares during the period. Brown Advisory Inc. raised its position in Novavax by 74.8% in the third quarter. Brown Advisory Inc. now owns 162,700 shares of the biopharmaceutical company’s stock worth $185,000 after acquiring an additional 69,600 shares during the period. Finally, State of Wisconsin Investment Board bought a new stake in Novavax in the second quarter worth about $230,000. 36.80% of the stock is currently owned by institutional investors and hedge funds.
Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with Analyst Ratings Network's FREE daily email newsletter.